Skip to main content
Top
Published in: Acta Diabetologica 4/2019

01-04-2019 | Obesity | Original Article

Light smoking is associated with metabolic syndrome risk factors in Chilean young adults

Authors: Evaline Cheng, Raquel Burrows, Paulina Correa, Carmen Gloria Güichapani, Estela Blanco, Sheila Gahagan

Published in: Acta Diabetologica | Issue 4/2019

Login to get access

Abstract

Aims

Metabolic syndrome (MetS) is a cluster of risk factors for cardiometabolic diseases. While cigarette smoking is associated with MetS in adults, young adulthood is an under-studied, susceptible period for developing long-term morbidity from MetS. We examined associations between cigarette smoking and MetS risk factors.

Methods

We studied 430 participants in Santiago, Chile who have been followed in a longitudinal cohort since infancy and assessed in adolescence for MetS. Participants were evaluated at 22 years from May 2015 to July 2017. Adiposity, blood pressure, and blood samples were measured. MetS was defined using International Diabetes Federation criteria. A continuous MetS score was calculated using z-scores. Participants self-reported cigarette and alcohol consumption using standardized questionnaires. We used multivariate regressions to examine associations between smoking and MetS risk factors, adjusting for sex, MetS in adolescence, alcohol consumption, and socioeconomic status.

Results

Thirteen percent of participants had MetS and 50% were current smokers. Among smokers, mean age of initiation was 14.9 years and consumption was 29 cigarettes weekly. Smokers had larger waist circumferences, higher BMIs, and lower high-density lipoprotein (HDL) cholesterol compared to non-smokers. Being a current smoker was significantly associated with higher waist circumference (β = 2.82; 95% CI 0.63, 5.02), lower HDL (β = − 3.62; 95% CI − 6.19, − 1.04), higher BMI (β = 1.22; 95% CI 0.16, 2.28), and higher MetS score (β = 0.13, 95% CI 0.02, 0.24).

Conclusions

Cigarette smoking at light levels (mean < 30 cigarettes weekly) was associated with MetS risk factors in a sample of Chilean young adults.
Literature
2.
go back to reference Yach D, Stuckler D, Brownell KD (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 12:62–67CrossRefPubMed Yach D, Stuckler D, Brownell KD (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 12:62–67CrossRefPubMed
3.
4.
go back to reference Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular Morbidity and Mortality. Diabetes Care 24:683–689CrossRefPubMed Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular Morbidity and Mortality. Diabetes Care 24:683–689CrossRefPubMed
5.
go back to reference Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care 30:8–13. https://doi.org/10.2337/dc06-1414 CrossRefPubMed Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care 30:8–13. https://​doi.​org/​10.​2337/​dc06-1414 CrossRefPubMed
14.
go back to reference Ferreira I, Twisk JWR, van Mechelen W et al (2005) Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults. Arch Intern Med 165:42–48CrossRefPubMed Ferreira I, Twisk JWR, van Mechelen W et al (2005) Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults. Arch Intern Med 165:42–48CrossRefPubMed
18.
go back to reference Lozoff B, Andraca I, De Castillo M et al (2003) Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. Pediatrics 112:846–854PubMed Lozoff B, Andraca I, De Castillo M et al (2003) Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. Pediatrics 112:846–854PubMed
19.
go back to reference Roncagliolo M, Garrido M, Walter T et al (1998) Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. Am J Clin Nutr 68:683–690CrossRefPubMed Roncagliolo M, Garrido M, Walter T et al (1998) Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. Am J Clin Nutr 68:683–690CrossRefPubMed
21.
go back to reference Graffar M (1956) Une méthode de classification sociale d’échantillons de population. Courrier 6:455–459 Graffar M (1956) Une méthode de classification sociale d’échantillons de population. Courrier 6:455–459
24.
go back to reference Brage S, Wedderkopp N, Ekelund U et al (2004) Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in danish children. Diabetes Care 27:2141–2148CrossRefPubMed Brage S, Wedderkopp N, Ekelund U et al (2004) Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in danish children. Diabetes Care 27:2141–2148CrossRefPubMed
26.
go back to reference Ragland D (1992) Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology 3:434–440CrossRefPubMed Ragland D (1992) Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology 3:434–440CrossRefPubMed
32.
go back to reference Walldius G, Jungner I (2004) Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255:188–205CrossRefPubMed Walldius G, Jungner I (2004) Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255:188–205CrossRefPubMed
34.
go back to reference Facchini F, Hollenbeck C, Jeppesen J et al (1992) Insulin resistance and cigarette smoking. Lancet 339:1128–1130CrossRefPubMed Facchini F, Hollenbeck C, Jeppesen J et al (1992) Insulin resistance and cigarette smoking. Lancet 339:1128–1130CrossRefPubMed
35.
go back to reference Cryer P, Haymond M, Santiago J, Shah S (1976) Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 295:573–577CrossRefPubMed Cryer P, Haymond M, Santiago J, Shah S (1976) Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 295:573–577CrossRefPubMed
Metadata
Title
Light smoking is associated with metabolic syndrome risk factors in Chilean young adults
Authors
Evaline Cheng
Raquel Burrows
Paulina Correa
Carmen Gloria Güichapani
Estela Blanco
Sheila Gahagan
Publication date
01-04-2019
Publisher
Springer Milan
Keywords
Obesity
Obesity
Published in
Acta Diabetologica / Issue 4/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1264-2

Other articles of this Issue 4/2019

Acta Diabetologica 4/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.